Hudis CA, Krop IE, Burstein HJ, Winer EP (2015) Adjuvant paclitaxel and
trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med
372
(2):
134-141, doi:10.1056/NEJMoa1406281 [doi]
Vaz-Luis I, Keating NL, Lin NU, Lii H, Winer EP, Freedman RA (2014) Duration and
toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a
population-based study. J Clin Oncol
32
(9): 927-934, doi:JCO.2013.51.1261
[pii];10.1200/JCO.2013.51.1261 [doi]
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY,
Dieras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K (2012) Trastuzumab
emtansine for HER2-positive advanced breast cancer. N Engl J Med
367
(19): 1783-
1791, doi:10.1056/NEJMoa1209124 [doi]
Wang SY, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP, Chen J (2014)
Cardiovascular events, early discontinuation of trastuzumab, and their impact on
survival. Breast Cancer Res Treat
146
(2): 411-419, doi:10.1007/s10549-014-3029-0
[doi]
